Literature DB >> 32456493

CYP17 gene polymorphic sequence variation is associated with hyperandrogenism in Kashmiri women with polycystic ovarian syndrome.

Sairish Ashraf1, Shayaq Ul Abeer Rasool2, Mudasar Nabi1, Mohd Ashraf Ganie3, Farhat Jabeen4, Fouzia Rashid5, Shajrul Amin1.   

Abstract

OBJECTIVE: Polycystic ovarian syndrome is a complex reproductive as well as endocrinological disorder characterized by anovulatory dysfunction, androgen excess and polycystic ovarian morphology. Hyperandrogenism is regarded as a cardinal feature of the disease. It is believed that the excess androgens are produced due to abnormality in steroid biosynthesis pathway wherein cytochrome P450, 17α-hydroxylase (CYP17) plays an imperative role. Therefore the objective of the present study was to analyze the T/C polymorphism in 5'UTR of CYP17 gene for its association with PCOS and hyperandrogenism in Kashmiri population.
METHOD: A total of 700 subjects which included 394 PCOS patients and 306 healthy controls were recruited for the study. Their anthropometric, biochemical and hormonal parameters were analyzed. DNA was extracted followed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) to analyze the relationship of CYP17 gene polymorphism with PCOS and hyperandrogenism in PCOS. RESULTS AND
CONCLUSION: The allelic as well as genotypic distribution did not show any significant difference between the cases and controls. However, PCOS patients with mutant genotype had significantly higher level of total testosterone and clinical features like FG score, alopecia than those of wild and heterozygous genotype, indicating association with hyperandrogenism in our Kashmiri population.

Entities:  

Keywords:  CYP; Polycystic ovary syndrome; SNP; hyperandrogenism

Mesh:

Substances:

Year:  2020        PMID: 32456493     DOI: 10.1080/09513590.2020.1770724

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  7 in total

1.  Androgen receptor coregulator long noncoding RNA CTBP1-AS is associated with polycystic ovary syndrome in Kashmiri women.

Authors:  Mudasar Nabi; Syed Mudasir Andrabi; Shayaq Ul Abeer Rasool; Sairish Ashraf; Imran Majid; Shajrul Amin
Journal:  Endocrine       Date:  2021-10-05       Impact factor: 3.633

2.  Aberrant H19 Expression Disrupts Ovarian Cyp17 and Testosterone Production and Is Associated with Polycystic Ovary Syndrome in Women.

Authors:  Zhaojuan Chen; Lan Liu; Xia Xi; Martina Burn; Cengiz Karakaya; Amanda N Kallen
Journal:  Reprod Sci       Date:  2021-10-15       Impact factor: 2.924

Review 3.  A Review on CYP11A1, CYP17A1, and CYP19A1 Polymorphism Studies: Candidate Susceptibility Genes for Polycystic Ovary Syndrome (PCOS) and Infertility.

Authors:  Roozbeh Heidarzadehpilehrood; Maryam Pirhoushiaran; Rasoul Abdollahzadeh; Malina Binti Osman; Maryam Sakinah; Norshariza Nordin; Habibah Abdul Hamid
Journal:  Genes (Basel)       Date:  2022-02-05       Impact factor: 4.096

4.  The Association of CYP17A1, CYP19A1, and SHBG Gene Polymorphisms in Polycystic Ovary Syndrome Susceptibility: A Systematic Review and Meta-Analysis.

Authors:  Chuan Xing; Han Zhao; Jiaqi Zhang; Bing He
Journal:  Front Physiol       Date:  2022-05-09       Impact factor: 4.755

5.  Common endocrine disorders associated with the polycystic ovary syndrome.

Authors:  Ibrahim A Abdelazim; Osama O Amer; Mohamed Farghali
Journal:  Prz Menopauzalny       Date:  2021-01-07

Review 6.  CYP17 T/C (rs74357) gene polymorphism contributes to polycystic ovary syndrome susceptibility: evidence from a meta-analysis.

Authors:  Xingyan Liu; Mei Xu; Min Qian; Lindong Yang
Journal:  Endocr Connect       Date:  2021-12-07       Impact factor: 3.335

Review 7.  An update on polycystic ovary syndrome: A review of the current state of knowledge in diagnosis, genetic etiology, and emerging treatment options.

Authors:  Hiya Islam; Jaasia Masud; Yushe Nazrul Islam; Fahim Kabir Monjurul Haque
Journal:  Womens Health (Lond)       Date:  2022 Jan-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.